Zofran and Nephrogenic systemic fibrosis - a phase IV clinical study of FDA data

Summary:

Nephrogenic systemic fibrosis is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Nephrogenic systemic fibrosis when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease) is found to be associated with 511 drugs and 671 conditions by eHealthMe. Check the latest studies of Nephrogenic systemic fibrosis.

On Jul, 07, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 63 people (0.07%) have Nephrogenic systemic fibrosis.

Could Zofran cause Nephrogenic systemic fibrosis?

Among these 63 people:

How long have people been on Zofran when they have Nephrogenic systemic fibrosis? *

What is the gender of people who have Nephrogenic systemic fibrosis when taking Zofran? *

female: 70.97 %
male: 29.03 %

What is the age of people who have Nephrogenic systemic fibrosis when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Nephrogenic systemic fibrosis? *

Skin Induration (an abnormally hard spot or area on the skin): 31 people, 49.21%
Pain: 29 people, 46.03%
Oedema Peripheral (superficial swelling): 28 people, 44.44%
Mobility Decreased (ability to move is reduced): 20 people, 31.75%
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue): 20 people, 31.75%
Skin Hypertrophy (skin cells enlarges): 19 people, 30.16%
Emotional Distress: 19 people, 30.16%
Gait Disturbance: 18 people, 28.57%
Joint Range Of Motion Decreased (disease of joint movement): 18 people, 28.57%
Stress And Anxiety: 18 people, 28.57%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 34 people, 53.97%
Headache (pain in head): 9 people, 14.29%
Nuclear Magnetic Resonance Imaging Abdominal: 9 people, 14.29%
Haemorrhage Intracranial (bleeding within the skull): 8 people, 12.70%
Asthma: 8 people, 12.70%
Anaemia (lack of blood): 7 people, 11.11%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 11.11%
Multiple Allergies (allergy to multiple agents): 7 people, 11.11%
Multiple Myeloma (cancer of the plasma cells): 6 people, 9.52%
Hypotension (abnormally low blood pressure): 5 people, 7.94%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Nephrogenic systemic fibrosis?

- Check whether Nephrogenic systemic fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (511 drugs)

Browse all the conditions that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (671 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.